Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial.

ABSTRACT:

Background

Autologous dendritic cell (DC) vaccines can induce tumor-specific T cells, but their effect can be counteracted by immunosuppressive mechanisms. Cisplatin has shown immunomodulatory effects in vivo which may enhance efficacy of DC vaccination.

Methods

This is a prospective, randomized, open-label phase 2 study (NCT02285413) including stage III and IV melanoma patients receiving 3 biweekly vaccinations of gp100 and tyrosinase mRNA-loaded monocyte-derived DCs with or without cisplatin. Primary objectives were to study immunogenicity and feasibility, and secondary objectives were to assess toxicity and survival.

Results

Twenty-two stage III and 32 stage IV melanoma patients were analyzed. Antigen-specific CD8⁺ T cells were found in 44% versus 67% an

SUBMITTER: Boudewijns S 

PROVIDER: S-EPMC7044256 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature